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Near infrared (NIR)-resonant gold nanoparticles (AuNPs) hold great promise
in cancer diagnostics and treatment. However, translating the theranostic
potential of AuNPs into clinical applications still remains a challenge due to
the difficulty to improve the efficiency and specificity of tumor delivery in vivo
as well as the clearance from liver and spleen to avoid off target toxicity. In
this study, endothelial colony forming cells (ECFCs) are exploited as vehicles
to deliver AuNPs to tumors. It is first demonstrated that ECFCs display a great
capability to intake AuNPs without losing viability, and exert antitumor activity
per se. Using a human melanoma xenograft mouse model, it is next
demonstrated that AuNP-loaded ECFCs retain their capacity to migrate to
tumor sites in vivo 1 day after injection and stay in the tumor mass for more
than 1 week. In addition, it is demonstrated that ECFC-loaded AuNPs are
efficiently cleared by the liver over time and do not elicit any sign of damage to
healthy tissue.
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1. Introduction
With over 10 million new cases every year
worldwide, metastatic cancer represents a
difficult disease to treat and a major cause
of morbidity and mortality.[1,2] Numerous
studies have led to a better understanding of
cancer at the genetic, molecular, and cellu-
lar levels, paving the way for new targets and
strategies for treatment.[3–5] Meanwhile,
much focus has been made to develop new
tools for cancer diagnosis.[6,7] Advances in
cellular and molecular imaging have led to
the development of various nanoparticle-
based diagnostic and/or imaging agents for
the detection of cancer.[6,8–10] Nevertheless
significant attempts are now being made to
improve therapeutic and diagnostic prop-
erties in a single effective nanomedicine
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solution: this concept, coined as "theranostics," comprises selec-
tive nanosystems that are able to diagnose, deliver, and monitor
the therapeutic response.[11–14]
Gold nanoparticles (AuNPs), due to their innate bioinertness,
quantum-size-related properties, such as highly tunable opti-
cal properties (e.g., plasmonically resonant optical absorbance
and fluorescence or Raman scattering enhancement),[15] have
shown remarkable promise in cancer diagnostics and treatment.
Indeed, as intrinsic theranostic agents, AuNPs stand out be-
cause of their remotely activatable anticancer activity (photother-
mal ablation)[16,17] and optical or hybrid imaging features (pho-
toacoustic imaging, PAI),[18] which removes the need of other
nanocarriers to rely on additional therapeutic and diagnostic
agents. AuNPs display optical absorption and scattering cross-
sections that are orders of magnitude greater than those of or-
ganic dyes, making them ideal contrast agents for a number of
applications in biomedical optics, such as PAI.
However, despite the number of reports on the successful
demonstration of Au nanomaterials for cancer theranostics[19,20]
and their biomedical applications,[21] their massive accumulation
in the liver and spleen due to resident macrophages that form
the mononuclear phagocyte system[22,23] is still an issue. Even
though much effort is being focused on functionalizing thera-
nostic nanoparticles with targeting moieties, several studies have
shown that the presence of specific ligands does not always result
into an increased accumulation in the tumor site, since it might
increase the formation of a protein corona hiding the nanopar-
ticle targeting ability.[24–26] Based on these considerations, solu-
tions able to boost the delivery of AuNPs to the target site are
still much needed. Of particular interest is the observation that
certain types of stem and immune cells, which have an innate
ability to target and infiltrate tumors, can be utilized as vectors
to deliver several types of anticancer payloads.[27–30] A contribu-
tion to these findings came from our recent study showing that
endothelial colony forming cells (ECFCs)[31] can be utilized to ex-
ploit the photothermal efficacy of near infrared (NIR)-resonant
chitosan-coated AuNPs (ChAumix).[32]
In this study, we explored the antitumor effects and the tumor-
homing efficiency of AuNP–ECFCs following single intravenous
injection into tumor-bearing mice and we assessed their biodis-
tribution in freshly excised mice organs at different time points
post administration by exploiting the PAI properties of AuNP-
enriched ECFCs.
It is worth emphasizing that a crucial parameter that governs
the effectiveness of cell-based nanoparticle delivery is the pay-
load capacity.[33] Since rapid recycling and exocytosis of internal-
ized nanoparticles can result in low loading capacity when relying
on nonspecific endocytosis, we compared the payload capacity of
ECFCs with that of more common models of tumor tropic cells,
such as murine macrophages RAW264.7 and mesenchymal stem
cells (MSCs), respectively. Nevertheless, we found that AuNPs are
eagerly taken up by ECFCs without impairing their viability or
cellular functions, and promoted unexpected antitumoral activi-
ties on melanoma cells.
We demonstrate that i) the loading capacity of AuNPs in
ECFCs enhances the photoacoustic (PA) signal detection and al-
lows a spectral tunability; ii) AuNPs happen to improve the un-
foreseen anticancer activity of ECFCs in vitro and in vivo; iii)
ECFCs efficiently deliver AuNPs to tumors in mice; iv) ECFC-
loaded AuNPs are efficiently cleared by the liver over time, thus
creating the premises for clinical translation.
2. Nanoparticle Uptake
2.1. Kinetics and Mechanism of Gold Nanoparticle Uptake
We previously demonstrated that ECFCs robustly internalize
AuNPs without eliciting cell toxicity.[32] Here, we monitored the
nanoparticle location within the cells by using multiphoton lumi-
nescence (MPL) microscopy and confocal microscopy. Because
gold nanoparticles exhibit MPL conversion, there is no need for
secondary labeling. Representative MPL images of ECFCs treated
with increasing concentration of AuNPs are shown in the upper
row of Figure 1a. The MPL emission from the metal nanopar-
ticles is clearly visible as green dots around the nucleus, and
shows a clear dose dependence. Results were confirmed by an
analysis performed with more standard optical tools. In the lower
row of Figure 1a and Figure S1 in the Supporting Information
fluorescence microscopy of ECFCs labeled with cytoskeletal F-
Actin staining phalloidin revealed that AuNPs accumulated and
formed intracellular aggregates (black spots) in perinuclear areas,
which increased in density with dose, as previously described.[32]
The cellular uptake of AuNPs was quantitatively evaluated using
inductively coupled plasma-atomic emission spectroscopy (ICP-
AES) after incubating ECFCs with AuNPs at the concentrations
of 100 × 10−6 and 150 × 10−6 m Au overnight (on) (Figure 1b).
High amounts of AuNPs were internalized by the cells with a
clear increase with dose. For both doses, only a negligible frac-
tion of gold was found to remain in the culture media. Thus, the
majority of AuNPs were taken up by the cells. AuNPs were then
conjugated with rhodamine and confocal microscopy was used
to assess the kinetics of uptake and retention within ECFCs. For
uptake, ECFCs were incubated with AuNPs at a concentration of
150 × 10−6 m Au for 3 h and overnight (15 h). Figure 1c shows
that the amount of AuNPs internalized by ECFCs is moderate
after 3 h and significantly increases after 15 h. In previous stud-
ies, cells were only subjected to a single treatment of nanoparti-
cles with increasing concentrations. With the aim to prove that
ECFCs are capable to internalize massive amounts of AuNPs, we
investigated whether multiple treatments of ECFCs with AuNPs
increase the intracellular load. In Figure 1d,e, transmission elec-
tron microscope (TEM) and ICP-AES analyses confirmed that a
double dose of AuNPs increased the intracellular load by almost
twofold compared to ECFCs treated for 15 h and more than eight-
fold compared to 3 h.
2.2. Comparative Study of AuNP Uptake
Since MSCs and macrophages showed tropism to tumors[27–30]
and thus, have been used as vehicles for cancer delivery, we in-
vestigated and quantified the amount of internalized AuNPs in
these two cell lines using optical microscopy (Figure 2a) and ICP-
AES (Figure 2b) and compared the results to those observed in
ECFCs. Images in Figure 2a reveal that RAW264.7 and MSCs in-
ternalized much lower amounts of AuNPs than the ECFCs after
overnight treatment. In particular, in the culture media of MSCs,
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Figure 1. Uptake of chitosan-capped Aumix by ECFCs. a) (Top row) Representative MPL images of ECFCs treated with increasing concentration of
AuNPs; (bottom row) fluorescence microscopy of ECFCs labeled with phalloidin (RED), which stains cytoskeletal F-Actin, and treated overnight with
increasing dose of AuNPs (black dots). b) ICP-AES analysis of gold content in 1.2 × 106 ECFCs and derived culture media (CM) of cells treated overnight
(on) with increasing dose of AuNPs. Statistical analysis was performed using unpaired Student’s t-test; error bars: mean ± SD (*p < 0.05). c) Confocal
microscopy of ECFCs treated for 3 h or overnight with AuNPs conjugated with rhodamine. d,e) Transmission electron micrographs and ICP-AES analysis
of ECFCs treated with one dose or two consecutive doses of AuNPs in 15 h. Significance was assessed by one-way ANOVA test followed by Newman–
Keuls post test. Error bars indicate mean ± SD; asterisk (*p < 0.05) indicates significant differences between cells treated with a double or a single dose
of AuNPs. All experiments were performed independently and at least in triplicate.
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Figure 2. Comparative AuNP uptake in three different tumor tropic cell
lines. a) Optical microscopy images of nonstained (upper panels) or
May–Grunwald–Giemsa stained (lower panels) untreated (CTRL) or cells
treated with increasing concentration of AuNPs. The inner gold content
appears as black spots in the cells. Experiments were performed in tripli-
cate. b) Percentage of administrated dose of AuNPs quantified by ICP.
we found massive aggregates of AuNPs that became more evi-
dent after May–Grunwald staining (lower row of Figure 2a). The
results of the ICP-AES analysis reported in Figure 2b, as pg of
gold per cell and as percent of particles taken up by cells with
respect to incubation dose (Table 1 in Figure 2), confirmed the
microscopic observations. To summarize the results of both anal-
yses, RAWs internalized particles better than MSCs, but ECFCs
outclassed both models by as much as a factor of two and almost
four, respectively. In quantitative terms, RAWs and MSCs were
found to contain 36% and 24% of total available gold, respectively,
while ECFCs incorporated up to 81% of AuNPs.
3. Gene Regulation in ECFCs Treated with AuNPs
and ECFC/A375-M6 Coculture
We previously demonstrated the ability of AuNPs to modulate
the expression of genes involved in cell motility, such as CXCR4.
Indeed, unexpectedly, we found a significant upregulation of
CXCR4 expression, and a sensible increase of cell migration indi-
cating an enhanced tumor tropism of Au enriched cells.[32] Inter-
estingly, there was no obvious impact of AuNP treatment on cell
viability,[32] or cell morphology (Figure 2a). Here, we demonstrate
that AuNPs are able to induce, at mRNA (Figure 3a) and protein
levels (Figure 3b), the expression of the urokinase plasminogen
activator receptor (uPAR), which is known to play a critical role
in the cell migration process. In light of these findings, we in-
vestigated whether the modulation of gene transcription related
to chromatin modifications. Surprisingly, we found an increase
of H3 acetylation in AuNP-treated ECFCs. ICP-AES analysis per-
formed on nucleic and cytosolic fractions detected the presence
of gold in the nuclei, which was calculated as 0.7% of incuba-
tion dose (Figure 3c). Next, in order to assess the translational
value of ECFCs as vehicles of AuNPs for theranostic purposes,
and to exclude the possibility that AuNP-induced gene activation
on ECFCs might support tumor growth and spreading, we inves-
tigated the effect of ECFC–AuNPs on melanoma cells through a
coculture model (Figure 3d). For this purpose, 1 × 106 carboxyflu-
orescein diacetate succinimidyl ester dye (CFSE)-labeled A375-
M6 (M6) cells were treated with 5 × 104 Far Red-labeled ECFCs
unloaded or loaded with AuNPs. The M6-AuNP-enriched ECFC
coculture images reported in Figure 3e clearly show the ratio be-
tween the two populations. 24 h later, both cell cocultures were
directed to a cell sorter analysis for CFSE and Far Red (Figure 3e).
The two positive cell populations isolated from the two cocul-
tures were clearly distinguished (Figure 3e). Sorted CFSE-labeled
melanoma cells were then stained with propidium iodide (PI)
for cell-cycle distribution analysis (Figure 3f). Untreated CFSE-
labeled melanoma cells (M6 CTRL) exhibited a relatively normal
pattern, with most cells in the S phase (≈58%), and a lower G0–
G1 phase (38%) peak of the cell cycle (Figure 3f). The treatment
of M6 with ECFCs alone caused G0–G1 cell cycle arrest (50% vs
38% in M6 CTRL), whereas AuNP-doped ECFCs led to a further
increase of M6 cell population at the G0–G1 phase from 50% to
59%. This indicates that pretreatment of ECFCs with AuNPs en-
hances the cell cycle arrest. Melanoma cells display an invasive
phenotype that allows them to degrade and infiltrate the extra-
cellular matrix (ECM) largely composed of a dense, crosslinked
network of collagen type I. To assess the effect of ECFCs on
melanoma invasiveness, we performed a collagen degradation
assay. As shown in Figure 3g, the presence of AuNP-unloaded
or loaded ECFCs on melanoma cell culture significantly blocks
the degradation of collagen elicited by melanoma cells.
Furthermore, the increase of ECFC/M6 ratio in the cell cocul-
tures was able to trigger apoptosis by inducing bleb formation,
as indicated by the black arrows in Figure 3h and in its enlarged
inset. The apoptotic effect of AuNP-unloaded or loaded ECFCs
on M6 cells was confirmed by fluorescent-activated cell sorter
(FACS) analysis with an increase of the percentage of cells in the
sub-G1 phase indicative of cell death (Figure 3i).
4. Photoacoustic Imaging of AuNPs–ECFC
4.1. Photoacoustic Imaging of AuNPs–ECFC in Test Objects
Photoacoustic imaging was performed in vitro using polyethy-
lene (PE) tubes (Figure 4a) filled with increasing concentration
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Figure 3. Assessment of antitumor activity of ECFCs on melanoma cells. a) mRNA levels of uPAR on untreated (CTRL) or AuNP-treated cells as deter-
mined by qRT-PCR analysis. The Student’s t-test was used to analyze the data. Error bars indicate mean ± SD; n = 3 experiments; *p < 0.05 indicates
statistical significance. b) Western blot analysis of uPAR and acetylate H3. GAPDH was used as loading control. c) ICP-AES analysis of nuclear and
cytoplasmatic fraction of ECFCs treated with 100 × 10−6m AuNPs. d) Optical microscopy images of melanoma (1 × 106 CFSE-A375-M6 cells)/ECFC (5 ×
104 FAR RED-ECFCs) coculture. e) Representative dot plots depicting FAR RED and CFSE fluorescence showing unstained and CFSE-stained melanoma
cells and unstained and FAR RED-labeled ECFCS. f) Flow cytometry analysis of melanoma cells stained with propidium iodide. The percentage of cells in
the different phases of the cell cycle was calculated by the ModFit program. g) Histograms of the collagenolytic activity of melanoma cells and melanoma
ECFC coculture expressed as percentage of collagen degradation with respect to positive controls obtained by the addition of exogenous collagenase.
Ctrl−: collagenolytic activity in the absence of cells and exogenous collagen; Ctrl+: collagenolytic activity in the absence of cells but in the presence of
exogenous collagenase; M6 CTRL: collagenolytic activity in the presence of M6 cells; M6+ECFC, M6+ECFCs100 collagenolytic activity in the presence of
coculture of M6+untreated ECFCs or +ECFC treated with 100 × 10−6m AuNPs. h) Optical microscopy images of M6 (1 × 106 CFSE-A375-M6 cells)/ECFC
(1 × 105 FAR RED-ECFCs) coculture. Black arrows indicate the presence of apoptotic cells. i) Histograms representing the percentage of melanoma cells
in sub-G1 phase analyzed by FACS. Significance was assessed by one-way ANOVA test followed by Newman–Keuls post test. Error bars indicate mean
± SD; asterisks (*p < 0.05) indicate significant difference from the M6 untreated cells (CTRL). Hash signs (#p < 0.05) indicate significant difference of
M6 treated with AuNP–ECFC from M6 treated with ECFC CTRL. All experiments were performed independently and at least in triplicate.
Adv. Sci. 2020, 2001175 © 2020 The Authors. Advanced Science published by Wiley-VCH GmbH2001175 (5 of 15)
www.advancedsciencenews.com www.advancedscience.com
Figure 4. PA characterization of AuNP–ECFCs: a) photograph of the PA phantom. b) Polyethylene tubes filled with increasing concentration of AuNP–
ECFCs up to 200 × 10−6m and ECFC control, on the left end, c) 3D PA/US reconstruction of the PA phantom with a biological layer put above the
polyethylene tubes; green scale: PA signal from the AuNP–ECFCs, grayscale: co-registered US signal. d) Plot of the PA spectral trend of AuNP–ECFCs
at different concentrations. e) Spectral fingerprint of the compound calculated by the normalization of PA signals from AuNP–ECFCs in comparison
with those from blank ECFCs. f) Photostability of AuNP–ECFCs under laser illumination at fixed wavelength (860 nm) over time. g) Samples of chicken
breast injected with a 50 µL bolus of AuNP–ECFCs; color scale: PA signal, grayscale: co-registered US signal; h) PA spectral response of injected and
noninjected regions; i) plot of contrast calculated as a function of wavelength.
of AuNP–ECFCs up to 200 × 10−6 m, ECFC control, and phos-
phate buffered saline (PBS) (Figure 4b,c). Typical PA patterns
are reported in Figure 4, showing the multispectral responses of
AuNP–ECFCs at different concentrations (12 × 10−6, 25 × 10−6,
50× 10−6, 100× 10−6, 150× 10−6, and 200× 10−6 m Au equivalent)
(Figure 4d–f) and the signals provided from PBS (Figure 4c,d)
and uncharged ECFCs (CTRL) dispersed in PBS (Figure 4c–f).
The PA signal intensity shows a linear trend with AuNP concen-
tration, with maximum intensity around 860 nm, in agreement
with the plasmon absorption band position (Figure 4d,f). In or-
der to identify relevant trends, the PA spectra acquired from all
AuNP–ECFC samples were normalized and analyzed (Figure 4e)
by calculating the percentage of variation (Figure S2, Supporting
Information). We found variations in the range between 1% and
8%, with values under 4% for 70% of the data. This confirmed
that the spectral trend was the same for all solutions (Figure 4e):
the plasmon peak position and PA spectral shape from the loaded
ECFC did not differ from reference solution of AuNP. The cellu-
lar clustering of the AuNPs did not modify their spectral trend
(Figure S2b, Supporting Information), while a significant vari-
ation of signal to noise ratio (SNR) was recorded. The PA sig-
nal provided from the AuNP–ECFCs exhibited a strong enhance-
ment with respect to that associated to an equivalent concentra-
tion of free AuNPs, without detectable spectral shift (Figure 4e).
These results suggest that the intracellular aggregation of AuNPs
leads to an increase of the efficiency of photoacoustic conversion,
which may originate from a combination of the effects of electro-
magnetic field enhancement with the emergence of hot spots,[34]
and of heat and stress confinement.[18] The quantification of this
effect in the concentration range until 200 × 10−6 m is reported in
Figure S2e in the Supporting Information. The evaluation of the
minimum detectable amount of AuNP–ECFCs provided a value
below 1 × 10−6 m, in terms of gold equivalent concentration in
the target volume.
The photostability of the AuNP–ECFCs was also studied by
prolonged laser illumination, selecting a stimulation wavelength
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of 860 nm, in order to get the maximum PA signal. Samples were
excited over 100 s (more than 500 laser pulses). The percentage
of variation among the acquired PA signals varied between 2.2%
and 3.4%, the related SNR between 30 and 45, and the contrast
to noise ratio (CNR) between 16 and 36 (Table S1, Supporting
Information).
In order to understand the effect of particle reshaping, we stud-
ied the PA signal of AuNP–ECFCs under direct laser stimula-
tion, without the interposition of any synthetic or biological ab-
sorber as reported in Figure S1c in the Supporting Information.
We found a spectral shift of the maximum peak in the first part of
NIR I optical windows from 860 to ≈700 nm, and a visible change
of color in the segment of the tubes that fell under the laser beam
(Figure S2d, Supporting Information).
In order to test more realistic tissue mimicking conditions,
imaging was also performed under a stack of chicken breast
muscle. A bolus of around 50 µL of AuNP–ECFCs 150 × 10−6
m was injected at different depth in samples of chicken breast
tissue (Figure 4g). The PA signal generated inside the tissue
was detectable until a depth of 1 cm (Figure S3, Supporting In-
formation) with intensity in the range between 0.8 and 0.3 ar-
bitrary units (Figure 4h,i). The PA signal produced from the
AuNP–ECFCs was up to four times more intense than that orig-
inating from control regions. The image contrast was calcu-
lated for each image (using the same region of interest (ROI)
dimension in a contralateral position) as reported in the Fig-
ure 4h,i, where S is the PA signal and b is the PA signal from the
background.
These findings collectively provide positive premises for the
use of AuNP–ECFCs for in vivo imaging.
4.2. Evaluation of AuNP–ECFCs Recruitment in Tumor Mass and
Biodistribution Study
PA tests were then performed on explanted melanoma lesions
and in main reticuloendothelial system organs such as the liver
and the spleen, where nanoparticles are reported to preferen-
tially accumulate. As shown in Figure 5a, the internal distribu-
tion of ECFCs was assessed by postprocessing algorithms based
on spectral unmixing components of each pixel based on the
pure spectral signature of ground components (i.e., oxy- and
deoxy-hemoglobin, AuNP–ECFCs). 3D PA–ultrasound (US) vi-
sualizations and reconstructions were used to highlight global
organ distributions. The endogenous components of oxy- and
deoxy-hemoglobin were unmixed from the spectral signal pro-
vided from the AuNP–ECFCs (Figure 5a). The 3D PA–US hyper-
spectral reconstruction[35,36] confirmed the accumulation of the
AuNP–ECFCs inside the tumor as well as in the liver and the
spleen. The assessment of internal distribution of ECFCs was
performed by studying the target organs after sacrifice after 1 day
and 1 week from injection. In the Supporting Information, we
report movies of rotating and slicing 3D PA–US reconstructions,
which convey a better feeling of the 2D and 3D distributions. The
comparison of AuNP–ECFC accumulation in the harvested or-
gans at 1 day (liver and spleen) and 1 week (liver) provides the
evaluation of the extraction or accumulation and release of the
AuNPs (Figures S4–S6, Supporting Information). We highlight
in the liver that 1 week after AuNP–ECFC administration, most of
Figure 5. Evaluation of AuNP–ECFC migration to tumor site and of biodis-
tribution 24 h after injection. a) 3D PA/US reconstruction of different bio-
logical targets after postprocessing spectral unmixing analysis of different
compounds: 1,2) Masses of melanoma; 3) liver; 4) spleen; green scale: PA
signal from the AuNP–ECFCs, red scale: PA signal from oxy-hemoglobin,
blue scale: PA signal from deoxy-hemoglobin, and gray scale: US signal. b)
Gold amount in the liver, spleen, lungs, kidney, and tumor mass 24 h af-
ter AuNP–ECFCs injection determined by ICP-MS. c) Histological assess-
ments of tumor tissue, liver, and spleen 24 h after AuNP–ECFC injection in
the tail vein (pink: cytoplasm stained with eosin; dark blue: nuclei stained
with hematoxylin).
the PA signal was associated to oxy- and deoxy-hemoglobin (Fig-
ure 6a; Figure S5, Supporting Information, red and blue colors
for oxy- and deoxy-hemoglobin, respectively), while after 1 day,
the signal from the AuNP–ECFCs was massive (Figure 5a; Fig-
ure S4, Supporting Information)
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Figure 6. Evaluation of AuNP–ECFC migration to tumor site and of biodis-
tribution 1 week after injection. a) 3D PA/US reconstruction of liver and
mass 1 week after AuNP–ECFC injection. b) Histological section of tumor
mass and liver 1 week after AuNP–ECFC administration. c) Liver, kidney,
spleen, and lungs 7 days after intravenous injection of AuNP–ECFCs com-
pared to the control group administered with unloaded ECFCs. All sections
were stained with hematoxylin–eosin.
The measurement of melanoma masses were performed by
volume reconstruction (Figure S8, Supporting Information).
The relative contribution of AuNP–ECFCs referred to the total
amount of PA signal was typically in the range 10–30% (Table S2,
Supporting Information). This findings were confirmed by ICP-
MS analysis performed in the harvested organs and tumor tis-
sues 1 day after injection: the highest accumulation was found in
the liver and spleen, followed by tumor masses (Figure 5b). His-
tological analyses confirmed the presence of AuNP–ECFCs[37]
(black spots in Figure 5c and the close-up) in the tumor tissue, the
liver but not in the spleen of mice sacrificed the day after AuNP–
ECFC administration. Considering the size of the organs, AuNPs
mostly accumulated in the liver, where the concentration of Au
was about four times higher than in the spleen. Nevertheless,
we followed the washout from these organs in 1 week: a macro-
scopic examination of the liver from mice sacrificed 1 week after
AuNP administration revealed a lack of black spots (Figure 6b),
thus confirming a significant washout of AuNPs, consistent with
the massive loss of relevant PA signal (Figure 6a; Figure S5, Sup-
porting Information). Histological analyses (Figure 6b) and PA–
US renderings (Figure 6a; Figure S7, Supporting Information)
demonstrate that gold is still retained in the tumor mass after 1
week from injection and that the intensity of relevant PA signal
is almost comparable to that detected after 1 day (Table S2, Sup-
porting Information). Moreover, the histological analysis of all
organs including the liver, spleen, kidney, and lung did not show
any morphological alteration after 7 days from administration of
AuNP–ECFCs compared to organs of control mice treated with
unloaded ECFCs (Figure 6c). No evidence of atrophy, hyperpla-
sia, necrosis, and fibrosis was observed with hematoxylin–eosin
staining. The examination of the parenchymal architecture did
not reveal any sign of steatosis or inflammation. These results
confirmed that a unique intravenous injection of 100 µg AuNPs
carried by 1 × 106 ECFCs efficiently reached tumors and did not
induce chronic toxicity.
4.3. Evaluation of the In Vivo Antitumor Activity of
AuNP-Enriched ECFCs
Since AuNP-enriched ECFCs exhibited antitumor potential in
vitro, we next sought to determine their antitumor activity in
vivo. In the light of the reported data showing, by photoacous-
tic imaging and the histological analysis (Figures 6a,b and 7a),
the presence of cargo cells in the tumor mass still 1 week af-
ter injection it was conceivable to select this time point to test
at the molecular level the antitumor property of AuNP–ECFCs.
Animals were treated as reported in the experimental procedure
and the tumor masses of the untreated mice (CTRL), ECFC-, or
AuNP-enriched ECFCs injected mice were removed (Figure 7a)
and subjected first to photoacoustic imaging to confirm the pres-
ence of gold in AuNP–ECFC-treated mice and then processed for
histological and molecular analysis. Histological analysis for pro-
liferating cell nuclear antigen (PCNA), a known cell proliferation
marker associated to the S phase of the cell cycle[38] showed a
strong exclusively nuclear staining in control samples (CTRL)
and ECFC-treated mice while a substantial reduction was ob-
served in AuNP–ECFC-treated group with only 20% of cells dis-
playing weak nuclear staining (Figure 7b). The above observa-
tion was further supported by the expression levels of PCNA
and Ki67 genes by real time PCR. Ki 67 is a ubiquitous human
nuclear protein expressed in G1-, S-, and G2-phases of the cell
cycle but not in the G0-phase
[39,40] and is therefore a measure
of the cell proliferation. A reduction of Ki-67 gene expression
and almost a complete disappearance of PCNA mRNA levels
was observed for AuNP–ECFC-treated mice. To further evaluate
the antitumor activity of AuNP-enriched ECFCs, the mRNA lev-
els of the matrix metalloproteinase 2 (MMP-2), which is highly
expressed in melanoma and associated to tumor progression
and invasion, was analyzed by real-time PCR (Figure 7c). As
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Figure 7. Evaluation of AuNP–ECFC antitumor activity in vivo. a) 3D US–PA volumetric reconstruction of oxygenated and deoxygenated hemoglobin
PA signal distribution in the tumor masses, with step size 130 µm, and the related cross view on the right; in red and blue scales, respectively, the PA
signal of oxygenated and deoxygenated hemoglobin; green scale, the PA signal of gold; gray scale for US signal. b) Top row representative PCNA stained
sections of tumors from untreated mice (CTRL), ECFC, or ECFC–AUNPs injected mice. Note in the latter sample the presence of AuNPs. Bottom row
representative images of sections in which the primary antibody (PCNA) was replaced by IgG of the same class. Images were acquired using 40× objective
and quantified using ImageJ (NIH). Histograms representing number of PCNA stained nuclei. c) Real-time PCR analysis performed on formalin-fixed
paraffin embedded (FFPE) melanoma tissue sections. Histograms represent relative PCNA, KI67, and MMP2-expression levels expressed as fold change
according to 2−ΔΔCT method, using GAPDH gene as calibrator. Error bars: mean± SD. Statistical analysis was performed using one-way ANOVA followed
by Newman–Keuls multiple comparison test. *p ≤ 0.05. # indicates significant difference from CTRL mice.
shown in Figure 7c, in the ECFC–AuNPs injected mice, we ob-
served a tenfold decrease in MMP-2 mRNA levels compared to
control mice.
4.4. Discussion and Conclusion
Personalized diagnosis and treatment with allogeneic or autol-
ogous cells are becoming a reality in the medical field.[41] Cyto-
toxic or engineered T cells are under clinical trial for the treat-
ment of hematopoietic or other malignant diseases.[42] Contrast
agent-tagged macrophages are used as cellular probes to image
early inflammatory processes in macrophage-rich conditions.[43]
More recently, also nonimmunological cells (MSCs and endothe-
lial progenitor cells, EPCs[41]) have been explored in preclin-
ical studies of therapeutic and regenerative medicine. EPCs
have been used in clinical trials for peripheral arterial disease,
pulmonary hypertension, liver cirrhosis, and coronary artery
disease.[44] The potential therapeutic role of ECFCs, a sub-
type of EPCs, has been proved in ischemic disease models
including myocardial ischemia, cerebral ischemia, and so on.
Nonetheless, MSC and macrophages are actually the most used
vectors in cell-delivered AuNPs, thanks to their innate tumor
tropism. However, a crucial issue for developing the potential
of this therapeutic approach and to achieve a "tailored ther-
apy," is the huge amount of cells either from autologous periph-
eral blood of cancer patients or immune privileged allogeneic
cells.
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Indeed, allogeneic MSCs are especially attractive due to their
potential to provide immediate availability and care at the time of
disease diagnosis. However, even though MSCs are believed to be
immune privileged, clinical implications of immune responses
to major histocompatibility complex (MHC)-mismatched MSCs
are still unknown and therefore preclinical and clinical studies
are necessary to answer this critical question.
The proliferation properties of macrophages are still object of
active research and a ready-to-use preparation for a single pa-
tient may require very long times that are not compatible with
a prompt therapeutic intervention.
The largest source of EPCs is represented by umbilical cord
blood (UCB), that offers immediate availability of cells with more
than 450 000 unrelated units banked worldwide and available for
potential clinical use.[41] Nevertheless CB-derived EPCs are rela-
tively tolerant and display a high proliferation potential.
The current study investigate a particular subtype of CB- de-
rived EPCs,[41] the ECFCs, as a vehicle of AuNPs for a theranostic
approach aimed at the diagnosis and thermoablative therapy of
melanoma through the photoacoustic and tunable thermic prop-
erties of ECFC–AuNPs payload.
We demonstrated in vitro that AuNP-loaded ECFCs are able
to generate higher photoacoustic signals than AuNPs alone, and
also display spectral fingerprints that enable a reliable detection
of labeled cells following intravenous injection. We ascribe the
enhancement of PA signal upon AuNP aggregation in intracel-
lular vesicles to an interplay of electromagnetic and thermody-
namic factors, such as heat and stress confinement. In vivo, we
demonstrated via PA–US and ICP analysis a great tumor-homing
efficiency of AuNP–ECFCs after a bolus intravenous adminis-
tration. Moreover, even though our biodistribution data showed
that AuNP–ECFCs preferentially accumulate in the liver after
24 h from injection, the almost complete washout of gold from
the liver after 1 week suggests an unexpected clearance. On the
contrary, we proved the permanence of AuNP–ECFCs inside the
tumor masses 1 week after administration. The tumor recruit-
ment of AuNP–ECFCs is mainly due to the chemotactic gradi-
ent of SDF-1 released in the tumor microenvironment.[45] Indeed
ECFCs express large amount of CXCR4, the specific receptor for
the chemokine SDF-1, on their surface. Normal tissues produce
little or no SDF1 and this constitutes a strong rationale to justify
the "temporary" passage of ECFCs in normal organs, followed
by complete clearance within a few days. Lastly, the absence of
histological damage such as fibrosis and tissue inflammation in
all organs including the liver, spleen, kidney, and lung 1 week af-
ter injection, along with the healthy behavior of animals, demon-
strates that AuNPs–ECFCs are safe and do not elicit any sign of
toxic effects. Unambiguously, these results collectively support
the advantage of ECFCs as delivery system for nanoparticle-based
diagnostic and therapeutic agents.
Another advantage of AuNP-loaded ECFCs is the high load-
ing efficiency that translates into a more sensitive detection of la-
beled cells. We also showed, for the first time, that the AuNP load-
ing capacity of ECFCs is much greater than those of MSCs and
macrophages, which have already been proposed for similar ap-
plications for their tumor tropism features.[27–30] Recent findings
showed that AuNPs are able to modulate the gene expression and
affect the chromatin status. We previously showed the capability
of AuNPs to increase the expression levels of CXCR4 in ECFCs,
and, here, we reported their effect on uPAR at mRNA and pro-
tein levels. Furthermore, we observed an increase of acetylated
histone 3 that counteracts the tendency of chromatin to fold into
highly compact structures, thus allowing DNA accessibility for
transcriptional factors. We also demonstrated, for the first time,
the antitumoral and anti-invasive effects of ECFCs on melanoma
culture with the cell cycle arrest in the G0–G1 phase and the
inhibition of the collagenase activity. Nevertheless, we also ob-
served that the effects of ECFCs on melanoma cells could shift
from cytostatic to apoptotic by doubling the number of ECFCs
on melanoma coculture. The in vivo data confirmed the antitu-
mor properties of our AuNP cell-based system by reducing the
expression of cell proliferating antigens such PCNA and Ki-67
and of the metalloproteinase MMP-2 at the mRNA level and by
inducing almost a complete disappearance of the nuclear PCNA
protein. Even though Arvizo et al.[46] have reported the ability of
inorganic unmodified gold nanoparticles to abrogate cell tumor
signaling thus leading to growth inhibition and metastasis, as
far as we know, no previous research has investigated the anti-
tumoral effects, in vitro and in vivo, of tumor tropic cells loaded
with unmodified NIR AuNP without exposure to NIR light. Based
on this and on our previous studies,[32] ECFC-loaded NPs 1) are
phagocytosis-prone cells with a high cytoplasm/nuclear ratio to
achieve an optimal loading of nanoparticles; 2) show a marked tu-
mor tropism and low cell retention in healthy organs; 3) represent
a tracking system with simple imaging methods; 4) have an effi-
cient thermotrasductive potential to produce locally controllable
destructive energy for tumor mass without affecting normal sur-
rounding tissues; 5) display inherent anti-invasive and antitumor
properties.
Collectively, our study represents an effort to combine multi-
ple therapeutic options, tracking and imaging in one platform to
increase the effectiveness of a single approach and taking into
account that ECFCs can be easily procured and are less likely to
react immunologically against the host, paves the way for future
investigation as a class of theranostic agents.
5. Experimental Section
Cell Lines: ECFCs, a subpopulation of EPCs, were isolated from
>50 mL human UCB of healthy newborns, as described in ref. [47] af-
ter maternal informed consent and in compliance with Italian legislation,
and analyzed for the expression of surface antigens (CD45, CD34, CD31,
CD105, ULEX, vWF, KDR, and uPAR) by flow-cytometry. ECFCs were cul-
tured in EGM2 medium (Euroclone) supplemented with 10% (v/v) fetal
bovine serum (FBS, Euroclone). Cells were incubated at 37 °C with 5%
CO2 saturation.
A375-M6 melanoma cells (M6) were isolated in the laboratory from
lung metastasis of SCID bg/bg mice i.v. injected with A375 melanoma
cells. A375 cells obtained from American Type Culture Collection (Man-
assas, VA) and M6 cells were independently validated by STR profiling at
the DNA diagnostic center BMRGenomics (Padova, Italy). Cells were am-
plified, stocked, and once thawed were kept in culture for a maximum of
4 months. Human MSCs were obtained from bone marrow aspirates of
donors who signed informed consent, and were expanded according to
published methods ref. [29]. MSCs were analyzed at P0 and P12 for the
expression of surface antigens CD45, CD14, CD44, CD166, CD90, CD73,
HLA-DP, -DQ, -DR, HLA-ABC, CD105, CD271 APC (FACSCalibur, Becton
Dickinson). Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Euroclone) supplemented with 20% (v/v) fetal bovine serum (Eu-
roclone). RAW264.7 murine macrophages were obtained from American
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Type Culture Collection (ATCC, Rockville, MD) and maintained at 37 °C
in DMEM medium (Euroclone) in a humidified 5% CO2 incubator main-
tained at 37 °C (Thermo Scientific, Waltham, MA). Cells were grown in
complete medium containing l-glutamine and 10% inactivated fetal calf
serum (Euroclone).
Preparation and Characterization of AuNPs: The preparation of
chitosan-capped Aumix nanoparticles (ChAumix, hereafter referred to as
AuNPs) was performed according to the prescriptions in refs. [16,32]. In
order to exploit these AuNPs as fluorescent tracers, and to follow their
internalization in cellular vectors, rhodamine 6G (R6G) was added. In par-
ticular, the protocols in ref. [48] were implemented, where AuNPs were
conjugated to R6G and used to label ECFCs. R6G was chosen for its high
fluorescence quantum yield and Raman scattering cross-section,[49] which
enables a simultaneous analysis of AuNP uptake and intracellular localiza-
tion.
In addition, it was verified that the AuNPs can be used as optical tracers
even without secondary labels, by exploiting their photoluminescence un-
der multiphoton excitation (see later in the description of the experimental
apparatus).
Here, the main steps for the preparation of AuNPs were briefly outlined
according to the recipe in ref. [16] and for their conjugation with R6G.
Tetrachloroauric(III) acid (HAuCl4), thiosulphate (Na2S2O3), and R6G
were purchased from Sigma-Aldrich and used as received. High-molecular
weight chitosan (≈106 kDa; 79% deacetylation degree) was obtained from
Heppe Medical. Ultrapure water (resistivity 18 MΩ cm) was obtained from
a MilliQ system from Merck Millipore.
525 µL of 3 × 10−3 m Na2S2O3 aqueous solution was rapidly added to
2.5 mL of 1.7 × 10−3 m HAuCl4 aqueous solution and vortexed for 20 s at
room temperature. The molar ratio [HAuCl4]/[Na2S2O3] was adjusted to
2.7, which conveys a plasmonic band peaking around 800 nm and exhibits
maximum intensity. The mixture was then left to react, and its spectrum of
optical extinction was checked via UV–vis spectroscopy every 10 min un-
til the position and shape of the plasmonic band stabilized within about
2 h. Even if the original protocol was reported to generate intrinsically sta-
ble nanoparticles,[16] it was found that chitosan helped to enhance the
colloidal stability of the suspension probably by the combination of elec-
trostatic and steric effects. In addition, the net positive charge of chitosan
favors the interaction between the cell membrane and the nanoparticles,
thus triggering their internalization. Capping with chitosan was obtained
by adding 93 µL of 10 × 10−3 m chitosan acidic solution (pH below 5), and
letting the mixture to react for 8 h at 25 °C under gentle stirring.
The further functionalization of the AuNPs with R6G was carried out by
adding 10 µL of 1 × 10−3 m R6G aqueous solution to 1 mL of the colloidal
suspension. The mixture was stirred for 8 h and purified by three steps
of centrifugation at 5500 rpm and decantation. Concentrated nanoparti-
cles were subsequently dispersed into 1 mL water. Exposure of the final
suspension to green laser light (532 nm) generated the typical orange flu-
orescence of R6G, thus evidencing the successful functionalization of the
Au nanoparticles.
Before the biological tests, all samples were sterilized with standard
autoclave treatment.
TEM Analysis of Au-Enriched ECFCs: ECFCs were seeded in 6-well
plates at a density of 1.5 × 105 cells per well and allowed to reach 70%
confluence. Next, cells were incubated with culture medium (2 mL per
well) containing suspensions of AuNPs at a concentration of 150 × 10−6
m Au for the indicated time points, then collected by trypsin treatment,
and centrifuged at 1000 rpm for 5 min in a 1.5 mL Eppendorf tube. The cell
pellet was then fixed in isotonic 4% glutaraldehyde and 1% OsO4, dehy-
drated, and embedded in Epon epoxy resin (Fluka, Buchs, Switzerland) for
electron microscopy. Ultrathin sections were stained with aqueous uranyl
acetate and alkaline bismuth subnitrate, and viewed and photographed
under a JEM 1010 transmission electron microscope (Jeol, Tokyo, Japan)
equipped with a MegaView III high-resolution digital camera and imaging
software (Jeol).
ICP-AES: ECFCs cells (3.0 × 105) were seeded on 10 cm dishes and
allowed to attach overnight. On the next day, cells were incubated with
culture medium containing AuNPs at increasing concentration, i.e., 50 ×
10−6, 100 × 10−6, and 150 × 10−6 m Au for the indicated time points. Cells
were then washed two times with PBS (Invitrogen), detached with a trypsin
treatment, and counted using a hemocytometer. Cell pellets were collected
by centrifugation, lyophilized, and placed in centrifuge tubes (one pellet
per tube). Then, 400 µL of aqua regia was added to each tube to com-
pletely dissolve the cells and their gold content. The amount of Au was
measured by Elan DRC II ICP-MS (Perkin Elmer, Waltham, MA). For the
comparative study, ECFCs, RAW264.7, and MSCs were seeded in 6-well
plates and treated for 24 h with chitosan-coated AuNPs at a concentration
of 150 × 10−6 m Au.
RNA Extraction, Semiquantitative and Quantitative PCR: Total RNA
was prepared using Tri Reagent (Sigma-Aldrich, Saint Louis, Missouri,
USA), agarose gel checked for integrity, and reverse transcribed with cDNA
synthesis kit (BioRad, Milano, Italy) according to the manufacturer’s in-
structions. Selected genes were evaluated by qualitative PCR using Blue
Platinum PCR Super Mix (Life Technologies, Monza, Italy) or real-time
PCR using SsoAdvanced Universal Green Mix (BioRad, Milano, Italy) with
7500 Fast Real Time PCR System (Applied Biosystems, Waltham, Mas-
sachusetts, USA). For real-time PCR, fold change was determined by the
comparative Ct method using 𝛽2-Microglobulin as normalization gene.
Amplification was performed with the default PCR setting: 40 cycles of
95 °C for 10 s and 60 °C for 30 s using SYBR Green-based detection. Primer
sequences (IDT, TemaRicerca, Bologna, Italy) were as follows:
18S-rRNA: sense, 5′-CCAGTAAGTGCGGGTCATAAG-3′; antisense, 5′-
GCCTCACATAA-CCATCCAATC-3′.
uPAR: sense, 5′- GCCCAATCCTGGAGCTTGA-3; antisense, 5′-
TCCCCTTGCAGCTGTA-ACACT-3′.
Cell Sorter Analysis: To evaluate the effects of ECFCs and AuNP-
enriched ECFCs on melanoma cell proliferation, A375-M6 cells were la-
beled with CFSE (Molecular Probe, LifeTtechnology) and ECFCs were la-
beled with Far Red (Far Red Cell Trace; Molecular Probe, Life Technologies).
In a first test, CFSE-labeled A375-M6 cells (CFSE-A375-M6) and Far Red-
stained ECFCs (FAR RED-ECFCs) were seeded together in 10 mm petri
dishes in EBM/DMEM medium at an initial density of 1 × 106 and 50 ×
104 cells, respectively. As control, the A375-M6 cells were seeded alone in
EBM/DMEM medium at the same density. In a second test, 1 × 106 CFSE-
A375-M6 cells were cocultured with 1 × 105 FAR RED-ECFCs. After 24 h co-
incubation, A375-M6 cells and ECFCs were harvested by trypsinization and
washed once with PBS. Cells were resuspended in PBS+ 0.1% Trypsin+ 20
× 10−3 m EDTA and sorted within 1 h of harvesting. Cells were separated
using BD cell sorter. CFSE-labeled cells were detected upon excitation with
a 488 nm argon laser using a 525/530 nm bandpass filter. FAR RED ECFCs
were detected upon excitation at 630 nm. Cells were separately analyzed
and used to establish original gating conditions. These gating limits were
used as part of the sort logic. Data were acquired to 600 000 intact A375-
M6 cells and 15 000 ECFCs determined by optical scattering gating, using
the acquisition software. FACS-sorted CFSE A375-M6 cells were used to
determine the number of cells in each phase of the cell cycle based on the
PI-generated DNA histogram data.
Isolation of Cytoplasmic and Nuclear Fraction: 1.2 × 106 ECFCs were
harvested and resuspended in lysis buffer (10 × 10−3 m HEPES pH 7.9,
50 × 10−3 m NaCl, 0.5 m sucrose, 0.1 × 10−3 m EDTA, 0.5% Triton X-
100, 1 × 10−3 m DTT, and a cocktail of proteinase inhibitors (Calbiochem,
Merck, Darmstadt, Germany)). Samples were centrifuged at 14 000 rpm
for 10 min to pellet nuclei and the cytoplasmic fraction was transferred to
a new tube. Nuclei were washed twice in a buffer containing 10 × 10−3 m
HEPES pH 7.9, 10 × 10−3 m KCl, 0.1 × 10−3 m EDTA, 0.1 × 10−3 m EGTA,
1 × 10−3 m DTT, and cocktail of proteinase inhibitors.
Cell Cycle Analysis: Cell-cycle distribution was analyzed via the DNA
content using the PI staining method. Cells were centrifuged and stained
with a mixture of 50 µg mL−1 PI (Sigma-Aldrich, St. Louis, MO, USA),
0.1% trisodium citrate, and 0.1% NP40 (or Triton X-100) (Sigma-Aldrich,
St. Louis, MO, USA) in the dark at 4 °C for 30 min. Stained cells were ana-
lyzed via flow cytometry (BD-FACS Canto, BD Biosciences, Franklin Lakes,
NJ, USA) using the red fluorescence of propidium-DNA.
Collagen Degradation Assay: A375-M6 cell suspensions and A375-M6
ECFC cocultures were copolymerized with Matrigel containing 2% FITC-
labeled collagen monomers (Molecular Probes). Digestion was allowed for
40 h at 37 °C and solid-phase Matrigel containing the cells was pelleted,
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whereas FITC released into the supernatant was analyzed by spectrofluo-
rometry. The 100% reference was obtained by complete collagenase diges-
tion of cell-free Matrigel lattices. Background fluorescence was obtained
by pelleting nondigested cell-free FITC collagen-enriched Matrigel layers.
Western Blot Analysis: Harvested cells were resuspended in 20 × 10−3
m RIPA buffer (pH 7.4) (Merk Millipore, Vimodrone, MI, Italy) containing
a cocktail of proteinase inhibitors (Calbiochem, Merck, Darmstadt, Ger-
many) and treated by sonication (Microson XL-2000, Minisonix, Farming-
dale, NY, USA).
Aliquots of supernatants containing equal amounts of protein (30 µg)
in Laemmli buffer were separated on Bolt Bis-Tris Plus 4–12% precast poly-
acrylamide gels (Life Technologies, Monza, Italy). Fractionated proteins
were transferred from the gel to a PVDF nitrocellulose membrane using
an iBlot 2 system (Life Technologies, Monza, Italy). Blots were stained
with Ponceau red to ensure equal loading and complete transfer of pro-
teins, and then blocked for 1 h at room temperature with 5% milk in PBS
containing 0.1% Tween. Subsequently, membranes were probed at 4 °C
overnight with mouse anti-uPAR antibody (1:500 Mon R4; ThermoFisher)
or rabbit anti-𝛼-tubulin antibody (1:1000 Cell Signaling) used to assess
equal amounts of protein loaded in each lane. Antirabbit IgG (whole
molecule)–Peroxidase antibody (Sigma, Cat#A0545) or antimouse IgG
(whole molecule)–Peroxidase antibody (Sigma, Cat#A9044) were used as
secondary antibodies; the enhanced chemiluminescence (ECL) procedure
was employed for development.
Confocal Microscopy Analysis: Cells were grown on glass coverslips,
washed twice with 1 mL of PBS, fixed for 20 min in 3.7% paraformalde-
hyde in PBS, and permeabilized with 0.1% Triton X-100 in PBS for 5 min.
Cells were incubated in blocking buffer (3% BSA and 0.1% Triton X-100 in
PBS) for 1 h at room temperature and then stained with phalloidin for 1 h.
Nuclei were stained with fluorescent Hoechst 33342 dye (DAPI) (10 µg
mL−1) (Invitrogen) for 15 min at RT. The coverslips containing the labeled
cells were mounted with an antifade mounting medium (Biomeda, Fos-
ter City, CA) and observed under a Bio-Rad MRC 1024 ES Confocal Laser
Scanning Microscope (Bio-Rad, Hercules, CA) equipped with a 15 mW
Krypton/Argon laser source for fluorescence measurements. Cells were
examined with a Nikon Plan Apo X60-oil immersion objective using an ex-
citation wavelength appropriate for Alexa 488 (495 nm). Series of optical
sections (XY: 512 × 512 pixels) were then taken through the depth of the
cells with a thickness of 1 µm at intervals of 0.8 µm (Z step). A single com-
posite image was obtained by the superimposition of 20 optical sections
for each sample.
MPL Analysis: As anticipated, the use of AuNPs was explored as mul-
tiphoton luminescence emitters[50,51] to infer information on their cellular
uptake, as a confirmation of the results obtained with R6G-marked AuNPs.
The multiphoton laser scanning confocal microscope was based on a
Zeiss LSM 510 Meta NLO system equipped with a Coherent Chameleon
Ti:Sapphire laser coupled to an upright Zeiss Axioskop 2 microscope (Carl
Zeiss Microscopy, Thornwood, NY). The ECFCs labeled with AuNPs (in-
cubation condition: 100 × 10−6 or 150 × 10−6 m Au equivalent for 24 h)
were seeded onto sterile cover glasses, fixed using 3.7 vol% formaldehyde
in PBS, and subjected to multiphoton imaging at an excitation wavelength
of 800 nm. The photoluminescence intensity of the cells at each time point
was obtained by averaging over at least 10 cells from multiple images. The
laser power at different time points did not show variations larger than 1%.
Photoacoustic Imaging In Vitro and Ex Vivo: PA experiment was per-
formed using the multimodality imaging platform Vevo LAZR by FUJIFILM
Visualsonics Inc. (Toronto). The PA properties and performances of ECFCs
were evaluated in test-object phantoms and ex vivo samples of biologi-
cal tissue. The test-object PA characterization was performed using a cus-
tom made phantom (Figure 4a) consisting of a polypropylene box loaded
with coplanar PE tubes (internal diameter = 0.58 mm; external diameter =
0.99 mm) that were loaded with AuNP–ECFCs at different concentrations
(Figure 4b) in the range of 12 × 10−6 to 200 × 10−6 m. The strong op-
tical absorbance of laser pulses from the AuNPs that originates the PA
emission may also trigger their photoinstability, due to overheating and
reshaping.[52] In order to prevent this nuisance, the optical fluence reach-
ing the AuNPs was limited by the interposition of a thin layer of chicken
breast placed over the PE tubes. Figures 5a and 6a report the 3D PA/US
reconstructions (38 µm motor-step) of this experimental configuration,
where the green-scale encoded the intensity of PA signal generated from
the AuNP–ECFCs, and the grayscale the co-registered US signal from the
PE tubes and the biological tissue. A second data set was obtained after
injection of a bolus of around 50 µL of AuNP–ECFCs within the chicken
breast, which served as reference biological matrix.[53]
Ex vivo tests were performed on harvested tissues of melanoma, liver,
and spleen of the mouse models, post-AuNP–ECFC treatment at time
points of 1 day and 1 week.
The PA multispectral analysis was performed in the first optical window
from 680 to 970 nm, in order to identify their specific fingerprint. The pho-
tostability was evaluated by keeping the AuNP–ECFCs under prolonged
laser illumination over time at fixed wavelength, and then calculating the
CNR, the SNR, and the percent coefficient of variation (%CV) as










where S is the acquired PA signal, b is the background, and 𝜎 is the stan-
dard deviation.
A comparative PA test was performed between the AuNP–ECFCs and
the AuNPs alone, in order to test the hypothesis of a differential PA ef-
fect produced when the AuNPs aggregate upon internalization in the
ECFCs. Moreover, 3D PA–US visualizations of harvested organs were re-
constructed to understand the AuNP–ECFC organ distribution and to
assess the global amount of PA signal. Spectral unmixing techniques
were applied to highlight the PA signal provided from the AuNP–ECFCs
with respect to that from endogenous dyes, such as oxy- and deoxy-
hemoglobin.[54]
In Vivo Experiments: The procedures involving animals were per-
formed in accordance with the ethical standards, the Declaration of
Helsinki and national guidelines, approved by the ethical committee of
Animal Welfare Office of Italian Work Ministry (protocol # 401/2015) and
conformed to the legal mandates and Italian guidelines for the care and
maintenance of laboratory animals.
Fourteen CD1 immunodeficient mice (6–8 weeks old; Charles River Lab-
oratories International) were injected subcutaneously with 100 µL of PBS
containing 1× 106 M6 cells. On day 14, when tumor measured ≈150 mm3,
one group of ten animals was injected intravenously with ECFCs preincu-
bated with AuNPs at a concentration of 150 × 10−6 m Au, and four mice
were injected with unloaded ECFCs. Animals were sacrificed at different
times after ECFC injection: one group of eight AuNP–ECFC animals and
one group of two unloaded ECFC mice (Control mice) were sacrificed 24 h
later, and one group of two AuNP–ECFC mice and another of two control
mice after 1 week.
Mice were anesthetized with a solution of ketamine (0.75 mg kg−1 body
weight) and xylazine (0.10 mg kg−1 body weight), and harvested samples
were fixed in 4% buffered formalin and directed to ex vivo PA analysis,
histological examination, and assessment of gold concentration.
The histological analysis of formalin fixed tumor mass and organs was
performed on paraffin-embedded sections (4 µm) using hematoxylin and
eosin. Stained slides were examined using an optical microscope.
To quantify the amount of gold in the tumor and organs, resected tis-
sues were prepared and analyzed using ICP-MS. Samples were frozen in
liquid nitrogen and weighed, then digested in aqua regia, and prepared as
previously described.[32]
To evaluate the antitumor effect of ECFC-enriched AuNPs in vivo, 12
male CD1 immunodeficient mice (6–8 weeks old; Charles River Laborato-
ries International) were injected subcutaneously with 100 µL of PBS con-
taining 1 × 106 M6 cells. On day 14, when tumor measured ≈150 mm3,
one group of four animals was injected intravenously with PBS (CTRL),
four animals with ECFCs preincubated with AuNPs at a concentration of
150 × 10−6 m Au (ECFCs+AuNPs), and four mice were injected with un-
loaded ECFCs (ECFCs). One week after the injection mice were sacrificed,
the tumor mass was removed and fixed overnight at 4 °C in formalin (5%
in PBS). Histological and molecular analysis were performed on paraffin
embedded sections.
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Immunohistochemistry: 4 µm thick paraffin-embedded tumor sections
were collected on glass slides. After deparaffinization, through a series of
solutions (100% xylene through 100% ethanol to 100% water), slides were
boiled for antigen retrieval and treated with 3% H2O2. The slides were sub-
sequently blocked with 1.5% BSA and incubated with PCNA primary anti-
body (1:200, Mouse mAb #2586 Cell Signaling) overnight at 4 °C. Probed
slides were then subjected to biotinylated mouse (1:1000, Vector Laborato-
ries, Inc., Burlingame, CA, USA) secondary antibody. The antibody binding
activity was detected using the avidin–biotin–peroxidase complex method
and diaminobenzidine tetrahydrochloride chromogen kit (Dako LSAB2;
Dako Corporation, Carpinteria, CA). Slides were counterstained with aque-
ous Meyer hematoxylin and mounted with glycerol for visual inspection
and photography. For negative control in the IHC procedures, primary an-
tibody was replaced by IgG of the same class.
Formalin-Fixed Paraffin-Embedded (FFPE) RNA Extraction Sample and
Quantitative RT-PCR (qRT-PCR): Twelve 10 µm thick sections were cut
from each block of FFPE tissue, transferred to 1.5 mL sterile tubes, and
processed using the PureLink FFPE Total RNA Isolation Kit (Invitrogen,
by Thermofisher) as previously described.[55] Briefly, RNA was extracted
by spin column purification according to similar basic principles: deparaf-
finization, followed by cell disruption with heated proteinase K, which is
capable of efficiently degrading proteins that were covalently crosslinked
with each other and RNA. Proteinase K incubation at high temperature
(60 to 70 °C) also removes part of the methylol additions induced by for-
malin fixation. After proteinase K incubation, RNA was isolated by alcohol
precipitation in a spin column purification step and then was stored at
−80 °C. Total RNA 260/280 OD ratios were consistently between 1.7 and
1.85, indicating high sample purity.
500 ng RNA was reverse-transcribed using Thermo Scientific Maxima
H Minus cDNA Synthesis Master Mix with dsDNase (Invitrogen, by Ther-
mofisher) according to manufacturer’s instructions.
Real-time RT-PCR was performed using ABI PRISM 7500 Sequence
Detection System instrument and software (Applied Biosystems, USA).
The relative expression level of the house-keeping gene (18S-rRNA) and
three target genes (Ki67; PCNA and MMP-2) was measured using SYBR
Green dye-based method. Relative mRNA expression of a target gene
within a specimen was calculated as 2−ΔCT, where ΔCT = CT(target gene) −
CT(housekeeping gene). The primer sequences were as follows:
Human Ki67: forward 5′-TCCTTTGGTGGGCACCTAAGACCTG-3′ and re-
verse 5′-TGATGGTTGAGGTCGTTCCTTGATG-3′.
Human PCNA: forward 5′-TCCTCCTTCCCGCCTGCCTGTAGC-3′ and re-
verse 5′-CGCGTTATCTTCGGCCCTTAGTGTA-3′.
Human MMP-2 forward 5′-CCCCAAAACGGACAAAGAG-3′ and reverse 5′-
CACGAGCAAAGGCATCATCC-3′.
Human 18S-rRNA: sense,5′-CCAGTAAGTGCGGGTCATAAG-3′; antisense,
5′-GCCTCACATAA-CCATCCAATC-3′.
Statistical Analysis: All the in vitro results were reported as means with
standard deviation (SD). For comparisons of more than two groups, a one-
way analysis of variance (ANOVA) followed by Newman–Keuls post test
was used. When only two groups were compared, statistical significance
was assessed with an unpaired Student’s t-test. p values of less than 0.05
were considered significant. Data were analyzed using GraphPad Prism 6.
The statistical tests used are stated in the figure captions. The elaboration
of the PA data was conducted using the following software: VevoLab (Fu-
jifilm Visualsonic Inc., Toronto) and Originlab. The statistical analysis to
check and compare the different kind of data, spectral acquisitions, and
photostability over time under prolonged laser illumination was done by
one-way ANOVA test with p ≤ 0.05 level of significance. The PA signal val-
ues acquired during the spectral analysis were carried out in the optical
windows from 680 to 970 nm with a step size of 5 nm. All of these PA val-
ues, for each concentration, were determined on three different set of data,
and then the mean value for each one wavelength and its standard devi-
ation was calculated. Finally, using one-way ANOVA (p ≤ 0.05), the other
set of spectral data, provided from the other colloidal solution at different
concentrations, was analyzed and compared in order to underline their PA
intensity differences correlated with the concentrations. The data set con-
cerning the photostability was acquired over 100 s, 5 values per second, for
an amount of over 500 points. Also, these datasets were compared in the
same way, calculating the PA signal mean values and the related standard
variation, and verifying by one-way ANOVA test (p ≤ 0.05), matching the
goodness of the results for the datasets at the same concentration (not
significantly different) and those at different concentrations (significant
differences). All the statistical tests confirmed the right match with the hy-
pothesis, in terms of spectral trends and the performing photostability. All
regarding biomedical imaging elaborations and analysis were done by the
Vevolab software. The Vevolab had allowed to check the different regions
of acquired PA images in order to find the spectral trends and to discrim-
inate the different PA spectral trends provided from the AuNP-enriched
ECFCs and the endogenous responsive molecules (oxygenated and deoxy-
genated hemoglobin) inside the treated samples. The spectral unmixing
tool operated on 2D and 3D acquisitions, in particular, the 3D calculations
for spectral discrimination were made on slice of 130 µm thickness on
sample volumes with dimensions of the order of 1.5 cm. The PA spectral
trends were calculated and evaluated on 59 points, while the photosta-
bility was checked and evaluated shooting the samples for over 500 laser
shots.
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